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A small-molecule inhibitor of SOD1-Derlin-1
interaction ameliorates pathology in an ALS
mouse model
Naomi Tsuburaya1, Kengo Homma 1, Tsunehiko Higuchi2, Andrii Balia3, Hiroyuki Yamakoshi2,
Norio Shibata 3, Seiichi Nakamura2, Hidehiko Nakagawa2, Shin-ichi Ikeda2, Naoki Umezawa2, Nobuki Kato2,
Satoshi Yokoshima4, Masatoshi Shibuya4, Manabu Shimonishi5, Hirotatsu Kojima6, Takayoshi Okabe6,
Tetsuo Nagano6, Isao Naguro1, Keiko Imamura7,8,9, Haruhisa Inoue7,8,9, Takao Fujisawa1 & Hidenori Ichijo1,6
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder. Despite its
severity, there are no effective treatments because of the complexity of its pathogenesis. As
one of the underlying mechanisms of Cu, Zn superoxide dismutase (SOD1) gene mutation-
induced ALS, SOD1 mutants (SOD1mut) commonly interact with an endoplasmic reticulum-
resident membrane protein Derlin-1, triggering motoneuron death. However, the importance
of SOD1-Derlin-1 interaction in in vitro human model and in vivo mouse model remains to be
elucidated. Here, we identify small-molecular-weight compounds that inhibit the SOD1-
Derlin-1 interaction by screening approximately 160,000 compounds. The inhibitor prevents
122 types of SOD1mut from interacting with Derlin-1, and signiﬁcantly ameliorates the ALS
pathology both in motoneurons derived from patient induced pluripotent stem cells and in
model mice. Our data suggest that the SOD1-Derlin-1 interaction contributes to the patho-
genesis of ALS and is a promising drug target for ALS treatment.
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Amyotrophic lateral sclerosis (ALS) is a progressive, late-onset neurodegenerative disorder characterized by theselective loss of both upper and lower motoneurons1.
Riluzole and Edaravone are the only two available treatments for
ALS that provide a modest improvement in survival2–4. Although
some clinical trials have been conducted over the past 20 years,
most of them have failed, at least in part because of the poor
understanding of the pathogenesis of ALS. Multiple motoneurons
toxicities have been proposed, such as oxidative stress, excito-
toxicity, proteasome dysfunction, endoplasmic reticulum (ER)
stress, abnormal mitochondrial function, and altered axonal
transport, but no consensus or precise mechanisms have been
elucidated5. Thus, there remains strong demand for ﬁnding new
and effective ALS treatments based on the molecular mechanisms
of ALS pathogenesis.
Mutations in the Cu, Zn superoxide dismutase (SOD1) gene are
frequently found in familial ALS (FALS) patients6. Although
SOD1 is a well-known antioxidant enzyme, mutant SOD1
(SOD1mut)-mediated FALS is now considered to result from
gain-of-toxic function(s) of SOD1 by mutation rather than from
changes in superoxide dismutase activity7–12. To date, more than
170 different mutations have been reported, but only a few
reports have tested the commonality of toxic mechanism(s) by
using a substantial number of different ALS-related SOD1mut.
Therefore, further investigation of SOD1mut-induced toxic
mechanism(s) is required for managing this fatal neurodegen-
erative disease.
We have previously reported that over 100 types of ALS-related
SOD1mut but not wild-type SOD1 (SOD1WT) commonly expose
the Derlin-1-binding region (termed the DBR) and interact via
the DBR with Derlin-1, one of the critical components of the ER-
associated degradation (ERAD) machinery13,14. Moreover, dis-
ruption of the SOD1mut-Derlin-1 interaction by expressing
Derlin-1-derived peptide (termed Derlin-1 (CT4)), which corre-
sponds to the binding site for the DBR and competes for binding
to SOD1mut, has been shown to be protective against SOD1mut-
dependent motoneuron loss in the mouse primary spinal cord
culture13. These ﬁndings suggest that the SOD1mut-Derlin-1
interaction is a common feature of SOD1mut-caused FALS
pathology and that inhibition of this interaction may be a
potential target for ALS treatment.
Protein–protein interaction (PPI) is an attractive target for
drug development because it plays central roles in large parts of
biological processes, and in pathological conditions. Thus, small
molecules that inhibit PPIs have potential as therapeutic medi-
cines themselves and also as useful experimental tools to elucidate
pathological mechanisms. Although it is considered as challen-
ging to identify small molecules that modulate PPIs, several
reports provide encouraging evidence for ﬁnding such com-
pounds15–25.
Here, we developed a high-throughput screening (HTS) system
to ﬁnd small-molecular-weight compounds that would function
as SOD1mut-Derlin-1 interaction inhibitors. By utilizing time-
resolved ﬂuorescence resonance energy transfer (TR-FRET)
technology, we successfully established a high-throughput, robust
assay system to measure the SOD1-Derlin-1 interaction. We
performed an HTS of 160,000 compounds in the public chemical
library (at the Drug Discovery Initiative (DDI), The University of
Tokyo) and found that an analog of one of the hit compounds
prevent 122 types of SOD1mut from interacting with Derlin-1.
The inhibitor signiﬁcantly ameliorates the ALS pathology in
motoneurons derived from patient induced pluripotent stem cells
(iPSCs) and delays the onset and prolongs the survival (14.5%
and 14.2% improvement, respectively) of ALS model mice
expressing SOD1G93A. Our data emphasize the importance of the
SOD1-Derlin-1 interaction as a common mechanism of
motoneuron toxicity in SOD1mut, and we provided a potential
mechanism-based ALS treatment.
Results
TR-FRET-based HTS assay for the PPI inhibitors. To identify
the inhibitors of the SOD1-Derlin-1 interaction, we ﬁrst estab-
lished an HTS system. We employed a TR-FRET-based assay for
the detection of SOD1-Derlin-1 interaction by using antibodies
labeled with either a donor or an acceptor ﬂuorophore (Fig. 1a).
Theoretically, when SOD1 and Derlin-1 are interacting, a donor
ﬂuorophore (Europium cryptate: Eu) and an acceptor ﬂuor-
ophore (d2) are in close proximity and generate the FRET signal.
In contrast, there is no FRET signal when the small molecules
inhibit the SOD1-Derlin-1 interaction. We previously mapped
each binding site: SOD1 (5-18), the amino-terminal 14 amino
acids of SOD1WT, was identiﬁed as the minimum essential DBR,
and the cytosolic carboxyl-terminal 12 amino acids, Derlin-1
(CT4), speciﬁcally interacts with SOD1mut 13,14. To identify the
combinations that efﬁciently generate FRET signal, lysates from
HEK293A cells transfected with various combinations of SOD1
and Derlin-1 constructs including each binding site were mixed
with the antibodies labeled with either Eu or d2. Among the over
1000 combinations of constructs and antibodies tested (Supple-
mentary Table 1), we obtained a robust signal from the cell lysate
expressing Flag-SOD1G93A and Derlin-1-HA using an anti-Flag
antibody labeled with Eu (Flag-Eu) and an anti-HA antibody
labeled with d2 (HA-d2), which was sufﬁcient for compound
screening (Z′-factor >0.9) (Fig. 1b). To conﬁrm that the FRET
signal was derived from the interaction of SOD1G93A with Derlin-
1, we performed the competition assay using each binding-site
peptide. Both the DBR-containing peptide (SOD1 (5-20); amino-
terminal 16 amino acids of SOD1) and the Derlin-1 (CT4) pep-
tide attenuated the FRET signal in a concentration-dependent
manner, clearly showing the requirement of the SOD1-Derlin-1
interaction for generating the FRET signal (Fig. 1c).
We screened a total of approximately 160,000 small molecules
using the inhibition of FRET signal as a readout. The Z′-factor of
all plates in the ﬁrst screening was set to be over 0.75, suggesting
that this assay system was sufﬁciently robust and reliable
(Supplementary Figure 1a). In this stage, 1460 compounds that
showed over 15% inhibition were selected for further validation in
the second screening (Fig. 1d and Supplementary Figure 1b).
The decrease in FRET signal may occur not only because of the
inhibition of SOD1-Derlin-1 interaction but also because of the
inhibition of interactions between the tags and the corresponding
antibodies. Alternatively, compounds may also target the energy
transfer itself by interacting with the emission or excitation
processes. To exclude such false-positive compounds, we
prepared the monomolecular FRET assay using HA-SOD1WT-
Flag with Flag-Eu and HA-d2 as a counter assay (Supplementary
Figure 1c). In the second screening, we reassessed the inhibition
of the SOD1-Derlin-1-derived FRET signal of 1460 positive
compounds in the ﬁrst screening and simultaneously checked the
effect of each compound on the monomolecular FRET signal of
HA-SOD1WT-Flag. Many of the compounds that were recon-
ﬁrmed to inhibit the SOD1-Derlin-1-derived FRET signal also
inhibited the monomolecular FRET signal (Fig. 1e, lower panel,
region A). However, some compounds attenuated only the
SOD1-Derlin-1-derived FRET signal with little effect on mono-
molecular FRET, suggesting that these compounds inhibit the
SOD1-Derlin-1 interaction (Fig. 1e, lower panel, region B).
Therefore, 131 compounds were selected, each showing over 15%
inhibition of the SOD1-Derlin-1-derived FRET signal without
inhibiting the monomolecular FRET signal by more than 15%
(Fig. 1e, lower panel, region B and Supplementary Figure 1b).
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Fig. 1 Screen of small molecules for SOD1-Derlin-1 interaction inhibitors. a TR-FRET-based interaction assay model showing the case of tagged SOD1 as a
target of the Eu-labeled antibody and tagged Derlin-1 as a target of the d2-labeled antibody. b, c FRET signals with Flag-Eu and HA-d2 shown as fold
changes from the FRET signal in non-transfected lysate. The data are shown as the mean ± s.d. b FRET signal using lysates from HEK293A cells transfected
with plasmids as indicated (n= 4). c Competition assay of FRET signal generated by Flag-SOD1G93A and Derlin-1-HA using indicated concentration of
SOD1 (5-20) and Derlin-1 (CT4) peptide. Lysates from HEK293A cells transfected with Flag-SOD1G93A and Derlin-1-HA were incubated with the indicated
concentration of each peptide for 16 h (n= 3). Light gray: with Derlin-1 (CT4) peptide; dark gray: with SOD1 (5-20) peptide. d Result of the ﬁrst screening.
The compounds are presented in order of inhibition rate. e, f Blue: inhibition (%) against FRET signal generated by Flag-SOD1G93A and Derlin-1-HA; red:
inhibition (%) against FRET signal generated by HA-SOD1WT-Flag. e Result of the second screening. The compounds are presented in order of inhibition
rate against the SOD1-Derlin-1-derived FRET signal. f Result of #56 in the third screening. The data are shown as the mean ± s.d. (n= 4). g Chemical
structure of #56
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Using a titration assay as the third screening, 44 compounds that
inhibited the SOD1-Derlin-1-derived FRET signal in a
concentration-dependent manner were further selected as
positive compounds (Supplementary Figure 1b, d).
In vitro compound validation identiﬁed #56 analogs. In the
FRET assay, positive compounds may still include compounds
that alter only the conformation of SOD1 or Derlin-1 and thereby
disrupt FRET signal without dissociation between the two pro-
teins. Thus, we performed an in vitro co-immunoprecipitation
assay by adding the compounds to the puriﬁed Flag-SOD1G93A-
Derlin-1-HA complex. Twelve compounds out of 44 became
positive in this assay (Supplementary Figure 2a–e). Among them,
we focused on one of the most prominent inhibitors, named
compound #56, because of its dose-dependency in the FRET
screening and its drug-like chemical structure deﬁned
according to the Lipinski’s rule of ﬁve, the absence of reactive
functional groups, and the exclusion of promiscuous hitters26,27.
The easiness to speculate the pharmacophore and to synthesize
the analogs was also taken into consideration (Fig. 1f, g and
Supplementary Figure 2d).
Structural analogs of compound #56 were commercially
available. More than 200 of those compounds were examined
for potential inhibitory effects on SOD1-Derlin-1 interaction.
Some of the #56 analogs that showed over 15% inhibition of the
SOD1-Derlin-1-derived FRET signal also inhibited the
interaction between SOD1 and Derlin-1 in in vitro immunopre-
cipitation assay (Fig. 2a). Moreover, we found inhibitors that
showed lower half-maximal inhibitory concentration (IC50)
values than #56 itself (Fig. 2b), including #56-20 and #56-26
(Figs. 2c, d, respectively). These data suggest that the basic core
structure of #56 analogs has an inhibitory effect on the SOD1-
Derlin-1 interaction.
#56-59 disrupts all SOD1mut-Derlin-1 interactions analyzed.
Unfortunately, none of the #56 analogs tested above showed
inhibitory activities in the cell-based co-immunoprecipitation
assay. To evaluate the possibility that the undesired interaction
with serum-derived substances was the cause of the inactivation,
we assessed the activity in serum-starved condition. Within the
serum-depleted medium, some of the compounds showed the
inhibition activity, suggesting that the undesired interaction in
the culture medium was one of the causes of the inactivity
(Supplementary Figure 3a). In addition, #56-26 was relatively
stable and showed low permeability, suggesting that the inability
might also be due to the low permeability of the plasma mem-
brane (Supplementary Figure 3b).
Although there were some compounds that inhibited the
SOD1-Derlin-1 interaction in serum-depleted condition, we have
previously reported that the serum depletion causes the
conformational change in SOD114,28. Thus, we synthesized new
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Fig. 2 Compound validation via in vitro assays. a Inhibition of SOD1G93A-Derlin-1 interaction by #56 analogs in the in vitro immunoprecipitation (IP) assay.
Puriﬁed SOD1G93A-Derlin-1 complex form HEK293A cell lysates transfected with Flag-SOD1G93A and Derlin-1-HA were incubated with the indicated
compounds for 16 h. Then, the complex was immunoprecipitated using anti-Flag beads, followed by immunoblotting (IB) analysis with the indicated
antibodies. b IC50 values of notable #56 analogs and #56 in the in vitro assay. IC50 values were calculated by generating standard curves. c, d Chemical
structure of #56-20 and #56-26
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culture medium containing serum. In an in vitro immunopreci-
pitation assay, two (#56-40, #56-41) out of six new compounds
worked as well as #56 itself, correlating with the result of FRET-
based assay (Fig. 3a, b and Supplementary Figure 3c). Moreover,
#56-40 showed an improved permeability and inhibitory effect on
the SOD1-Derlin-1 interaction even in a cell-based co-immuno-
precipitation assay (Fig. 3c and Supplementary Figure 3b).
However, this compound has the inconsistent effect, suggesting
that the effective concentration depends on cellular conditions.




























































20 10 5 20 10 5 20 20 2010 10 105 5 5








































































Flag-SOD1 G93A + Derlin-1-HA













































































Fig. 3 Identiﬁcation of cell-permeable compounds. a Chemical structure of newly synthesized #56 analogs. #56-43 is the resynthesized #56-10.
b Inhibition of SOD1G93A-Derlin-1 interaction by new #56 analogs in in vitro IP assay. The SOD1G93A-Derlin-1 complex puriﬁed from lysates
transfected with Flag-SOD1G93A and Derlin-1-HA was incubated with the indicated compounds for 16 h and analyzed by IP-IB with the indicated antibodies.
c, d Inhibition of SOD1G93A-Derlin-1 interaction by #56 analogs in a cell-based IP assay. HEK293A cells transfected with indicated plasmids were treated
with the indicated compounds for 24 h, and lysates were analyzed by IP-IB with the indicated antibodies. c Inhibition of SOD1G93A-Derlin-1 interaction by
the same compounds as in the in vitro assay b in a cell-based assay. Compound #66 is used as a positive control of a cell-permeable inhibitor, although the
resynthesized #66 does not show any activities. d Two cell-permeable SOD1G93A-Derlin-1 interaction inhibitors in a cell-based IP assay. e, f Chemical
structure of #56-40 and #56-59. g Inhibitory activities of other compounds containing tertiary amide groups, #56-102-105, in the cell-based IP assay as in
c, d. h Chemical structure of #56-102, 103, 104, and 105
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more stable inhibitor in cell-based assay, #56-59 (Fig. 3d–f).
Through the further evaluation of newly synthesized #56
derivatives, we found that the character of potent inhibitors in
cell-based assay is provided by the replacement of hydrogen with
alkyl groups at the amide bond, turning that amide into a tertiary
amide (Fig. 3g, h). Testing several derivatives with a tertiary
amide, we found even more potent inhibitor, #56-111 (Supple-
mentary Figure 4a, b).
SOD1G93A, which we used for the above screening steps, is a
representative SOD1mut among 122 types of ALS-related
SOD1mut that interact with Derlin-1. Thus, we next examined
whether #56-59 could also inhibit the interactions of Derlin-1
with 122 types of SOD1mut in the cell-based co-immunopreci-
pitation assay. #56-59 clearly attenuated the interactions between
Derlin-1 and all tested SOD1mut (Supplementary Figure 5a–h).
These results suggest that ALS-related SOD1mut commonly
possess a similar mechanism of interaction with Derlin-1,
consistent with our previous ﬁndings of the importance of DBR
exposure in SOD1 for the interaction with Derlin-114,28,29.
SOD1WT is known to form homodimers, and Derlin-1 forms
homomeric and heteromeric complexes with Derlin family proteins
and with other ERAD components such as Hrd130. Under the
same conditions as those in which #56-59 inhibited the SOD1-
Derlin-1 interaction, these interactions were not affected,
suggesting that #56-59 inhibits the SOD1-Derlin-1 interaction
with some speciﬁcity (Supplementary Figure 6).
#56 analogs target SOD1 DBR. There are two putative modes of
action of PPI inhibitors: intervention by direct binding to the
interface or allosteric interference. To reveal the mechanism of
#56-mediated PPI inhibition, we evaluated the inhibition activity
of #56 analogs against the SOD1-Derlin-1 interaction using full-
length proteins and/or fragments containing binding sites in the
in vitro assay. Due to the low activity of #56-59 in vitro, two
prominent in vitro inhibitors, #56-20 and #56-26, were assessed.
Both of them inhibited all combinations of the interaction
(Fig. 4a). The inhibition of the interaction between SOD1 (1-20)
and Derlin-1 (CT4) suggested that #56 analogs exert their
activities by interacting with the binding region of either SOD1 or
Derlin-1. To identify the direct binding target of #56 analogs, we
tried the surface plasmon resonance (SPR) method with bioti-
nylated peptide as a ligand and #56 analogs as an analyte.
However, the interaction could not be detected probably due to
the relatively weak interaction and low solubility of the com-
pounds (Supplementary Figure 7a). Thus, we next performed
ﬂuorescence polarization (FP) assays in the presence of SOD1 (5-
20) peptide or Derlin-1 (CT4) peptide, utilizing the ﬂuorescence
properties of #56-20 per se. The degree of FP increased in the
presence of SOD1 (5-20) peptide rather than the Derlin-1 (CT4)
peptide, suggesting that #56-20 preferentially and directly inter-
acts with the SOD1 DBR (Fig. 4b). We also compared the binding
ability of #56-20 to the full-length recombinant SOD1WT and
SOD1G93A. The preferential interaction of #56-20 with
SOD1G93A was observed (Kd= 81.1 μM and Supplementary
Figure 7b). This is consistent with our model in which SOD1mut
possess a DBR-exposed conformation and that #56-20 interacts
with the DBR14,29.
Next, to conﬁrm the target of the compounds within the cells,
we embedded benzophenone as a photoactivatable crosslinking
moiety, and a biotin as a tag to #56-59, a potent inhibitor in cell-
based assay. We named this compound Photo-Biotin-PEG3-#56-
59, PB56 for short (Fig. 4c, right). Although it was less potent
than the original compound (#56-59), PB56 also inhibited the
SOD1-Derlin-1 interaction in a dose-dependent manner (Sup-
plementary Figure 7c). In the crosslinking and pull-down assays
using SOD1G93A-transfected or Derlin-1-transfected cells treated
with PB56, we clearly observed the biotin-labeled band at the
same position of monomer Flag-SOD1G93A and high-molecular
smear bands probably representing sodium dodecyl sulfate
(SDS)-resistant SOD1G93A aggregates, suggesting that
PB56 selectively binds to SOD1 and not Derlin-1 (Fig. 4c, left).
Pre-treatment with #56-59 competitively displaced the binding of
PB56 to SOD1G93A, indicating that the common basic structure
of #56-59 in PB56 mediated the interaction with SOD1 (Fig. 4d).
Moreover, we conﬁrmed that PB56 interacted with SOD1G93A
more strongly than SOD1WT within the cells (Fig. 4e).
Additionally, we evaluated the effects of #56 analogs to SOD
activity in vitro. Both #56-20 and #56-26, which possess strong
inhibitory activity on the SOD1-Derlin-1 interaction in vitro,
showed no effects on SOD activity (Supplementary Figure 7d).
Taken together, these data suggest that #56 analogs might
speciﬁcally inhibit the interaction with Derlin-1 by directly
binding to the SOD1 DBR without affecting the enzymatic
activity of SOD1.
#56-59 ameliorates the pathology of ALS. Finally, we evaluated
the therapeutic effects of #56 analogs in in vitro human model
utilizing ALS patient iPSCs as well as in in vivo ALS mouse
model. Recently, we have characterized and established the
in vitro ALS model system by utilizing patient iPSCs31. Therefore,
we treated #56-40 and #56-59 to motoneurons derived from ALS
patient iPSCs with L144FVX mutation in SOD1 (ALS1). Although
#56-40 was less effective, probably because of the narrow effective
dose, treatment with #56-40 and #56-59 increased the survival of
ALS motoneurons (Fig. 5a). Then, we further investigated the
effect of #56-59 to other iPSC-derived motoneurons. The number
of motoneurons generated from healthy control-derived iPSC was
not increased in the presence of #56-59, indicating that the
increase of ALS motoneurons with #56-59 was not due to the
improvement of differentiation efﬁciency or survival independent
of ALS pathology (Supplementary Figure 8a). Although #56-59
did not improve the viability of motoneurons generated from
ALS3 (SOD1G93S), it restored the motoneuron survival of ALS2
(SOD1L144FVX) (Supplementary Figure 8a). These data suggested
that #56-59 could ameliorate SOD1mut toxicity in in vitro human
ALS model. The conformational changes in SOD1WT have been
reported in FALS with other ALS-causative gene mutations,
including FUS and TDP-43 32. Thus, we examined the effect of
#56-59 on motoneuron toxicity with TDP-43 mutant; however,
#56-59 failed to improve the survival of ALS4 motoneurons
(TDP-43M337V) at least in this condition (Supplementary
Figure 8a).
Next, we performed continuous delivery of the compounds to
SOD1G93A transgenic male mice by using osmotic pumps.
Because we were concerned that the efﬁcacy of the compounds
might be compromised by a limited ability to cross the
blood–brain barrier and to access the target motoneurons,
intracerebroventricular (i.c.v.) cannulation was chosen as the
method for delivery. The start point of administration was set at
22 weeks of age, approximately 6 weeks before the usual onset
timing as deﬁned in our previous study13. We infused the mice
with dimethyl sulfoxide (DMSO) as control, 1 mM #56-40, and
3 mM #56-59 at a ﬂow rate of 0.15 μl h−1. The onset, deﬁned as
motor function deﬁcit observed in rotarod performance, and the
survival time were monitored. While mice infused with #56-40,
which might be out of effective dose, were comparable to control
mice, mice infused with #56-59 showed signiﬁcantly delayed
onset, by a median of 4.5 weeks (14.5% improvement), and also
showed signiﬁcantly prolonged survival, by a median of 5 weeks
(14.2% improvement) (Fig. 5b, Supplementary Figure 8b, and
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Fig. 4 #56 analogs target SOD1 DBR. a In vitro IP assay with various SOD1-Derlin-1 complexes. SOD1-Derlin-1 complexes puriﬁed from lysates transfected
with the indicated plasmids were incubated with #56-20 or #56-26 for 16 h and analyzed by IP-IB with the indicated antibodies. b FP analysis of #56-20 in
the presence of indicated concentration of SOD1 (5-20) and Derlin-1 (CT4) peptide. Here, 250 nM #56-20 was incubated with the indicated concentration
of each peptide for 6 h, and FP was measured. Blue: Derlin-1 (CT4); red: SOD1 (5-20). The data are shown as the mean ± s.d. (n= 3). c–e Pull-down assay
using PB56. HEK293A cells transfected with indicated plasmid were treated with 200 μM PB56 for 24 h followed by UV light irradiation for 1 h. Lysates
were analyzed by IP-IB with the indicated antibodies. c Pull-down assay by Flag-SOD1G93A or Derlin-1-Flag. Chemical structure shows PB56 (blue: #56-59
(active part); black: benzophenone with polyethylene glycol (PEG) as spacers; red: biotin). d Competition assay with the pre-treatment of 20 μM #56-59
for 12 h. e Pull-down assay by Flag-SOD1G93A or Flag-SOD1WT
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Supplementary Table 2). Consistent with these results, the
number of motoneurons detected by Nissl staining of lumbar
spinal cord sections at 31 weeks of age was signiﬁcantly increased
in #56-59-treated ALS model mice (Fig. 5c, d). These data clearly
show that the SOD1-Derlin-1 interaction inhibitor can ameliorate
ALS pathology both in in vitro human model and in vivo mouse
model, demonstrating the importance of the SOD1-Derlin-1
interaction in the pathogenesis of SOD1mut-induced FALS and
the potential of the SOD1-Derlin-1 interaction as a therapeutic
target in ALS.
Discussion
In the present study, we designed and developed a high-
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Fig. 5 Inhibiter of SOD1-Derlin-1 interaction, #56-59, ameliorates ALS pathology. a Effects of #56 analogs on motoneurons derived from ALS patient iPSCs
with L144FVX mutation in SOD1 (ALS1). The ratios of surviving motoneurons (day 14/day 7 (%)) are shown as the mean ± s.d. (n= 6; *P < 0.05, also see
Methods for statistical test). b Analysis of onset (DMSO: n= 10, #56-40: n= 11, #56-59: n= 12) and survival (DMSO: n= 14, #56-40: n= 11, and #56-59:
n= 15) in SOD1G93A transgenic mice (SOD1 G93A Tg) continuously infused with #56 analogs by i.c.v. cannulation. Onset was determined by motor
function deﬁcit seen in rotarod performance. Black: DMSO treatment (control); green: #56-40 treatment; red: #56-59 treatment. Mice were followed in
this survival study for 58 weeks, and the survival time of one mouse that did not show paralysis is shown as a tick on the line. Statistical analysis was
performed using the Kaplan–Meier method followed by the log-rank test and the Gehan–Breslow–Wilcoxon test (*P < 0.05, n.s.: not signiﬁcant).
c Representative Nissl stain image of the lumbar spinal cord section (L2–L5) of indicated mice. All motoneuron counts were performed in a blinded fashion.
Scale bar= 20 μm. d Quantiﬁcation of motoneuron counts in c. Five sections per mouse were counted, and the data are shown as the mean ± s.e.m. WT
mice: n= 4; DMSO-treated and #56-59-treated SOD1 G93A Tg: n= 8 in each group, *P < 0.05: signiﬁcance was calculated using Student’s t test
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interaction between two proteins, SOD1 and Derlin-1 (Fig. 1a–c).
We screened approximately 160,000 compounds and selected one
potential scaffold, #56 (Fig. 1d–g). We found that some analogs of
#56 also possessed inhibitory activities in vitro (Fig. 2a–c).
Moreover, newly synthesized #56 analogs inhibited the SOD1-
Derlin-1 interaction in cell-based assays (Fig. 3c, d, g). One of
these inhibitors, #56-59, exerted its activity on all types of
SOD1mut-Derlin-1 interaction that we previously reported14
(Supplementary Figure 5a–h). Furthermore, we show that the
SOD1-Derlin-1 interaction inhibitor can ameliorate ALS pathol-
ogy both in in vitro human model and in vivo mouse model
(Fig. 5).
We used two inhibitors, #56-40 and #56-59, to assess the effect
to the ALS pathology. However, unlike #56-59, #56-40 showed
only modest effects to the ALS pathology (Fig. 5a, b). Our con-
cern was that the effective concentration of #56-40 was in a very
narrow range. Thus, we assume that the dose of #56-40 might be
insufﬁcient to show a therapeutic effect on ALS model mice under
these conditions. Moreover, ALS4 motoneurons showed even a
vulnerability to #56-59. The ALS motoneurons would be feeble,
and the effective dose of #56-59 might be different among iPSC
lines. The failure of improvement in ALS3 and the signiﬁcant
reduction in ALS4 could be caused by the toxicity of #56-59.
The detected concentration of #56-59 in the brain and spinal
cord of the mice were very low (Supplementary Figure 8b and
Supplementary Table 2). In addition, we could not evaluate the
inhibition activity in vivo, because the level of the SOD1-Derlin-1
interaction varies even in the non-treated ALS model mice
(Supplementary Figure 9a). Taking account of the unbound
fractions within the serum, the effective concentration of #56-59
could be estimated between 0.25 to 1 μM in cell-based immu-
noprecipitation assay (Supplementary Figure 4a and Supple-
mentary Figure 8c). One of the possible reasons of this
discrepancy is the modiﬁcation of #56-59. #56-40 showed a
relatively unstable character (Supplementary Figure 3b).
Although HEK293A cells and the cells in central nervous system
do not express typical metabolizing enzymes compared to hepatic
cells, #56-40 and probably #56-59 could be metabolized in cells
and in vivo. In the present method that we measured the con-
centration of #56-59, the modiﬁed compounds could not be
estimated. Therefore, it is possible that the modiﬁed #56-59,
which we could not identify in this study, contributed to the
inhibition of SOD1-Derlin-1 interaction in the present assays.
Another possibility is the difference of the treatment time
course. In the long-term treatment in vivo, #56-59 could occupy
the DBR of newly synthesized SOD1mut before its interaction
with Derlin-1. Thus, #56-59 would be able to efﬁciently inhibit
the SOD1-Derlin-1 interaction compared to the cell-based
immunoprecipitation assay, where #56-59 might dissociate the
pre-formed complexes. It is also possible that as we could ﬁnd the
increase of #56-59 in spinal cord at 5 weeks of infusion (Sup-
plementary Figure 8b and Supplementary Table 2), the longer
continuous infusion would reach higher concentration.
Notably, one ALS model mouse treated with #56-59 did not
show any symptoms until 58 weeks of age. Although it is unclear
whether #56-59 could really suppress the pathology completely in
some population or whether additional factor(s) might exist,
further improvement of the administration method, including
doses, timing of initial administration, and pharmacokinetics,
should provide us with more effective treatment for ALS
pathologies.
In the present study, we administered the compounds before
the appearance of defects in motor function. Our compound
delayed the onset of the disease, suggesting that the SOD1-Derlin-
1 interaction is involved in the onset of ALS, and earlier treatment
might improve the phenotype more effectively. The early
diagnosis of conformation-disordered SOD1 using our ELISA
system that can easily detect the DBR-exposed SOD1 may enable
us to perform a differential diagnosis of the applicable patients
before onset and to provide pre-onset treatment14,26.
We have previously reported that ER stress evoked by the
SOD1-Derlin-1 interaction activates ASK1, and ASK1 deﬁ-
ciency prolonged the survival of ALS model mice by improving
the disease progression but not onset13. Moreover, the
administration of ASK1 inhibitors showed the reduction of
the glial cell activity33, which is known to contribute to the
progression of the pathology34,35. On the other hand, the #56-
59 treatment had little effect on the progression and did
not show signiﬁcant suppression of gliosis (Supplementary
Figure 9b). Thus, we estimate that the SOD1-Derlin-1 inter-
action may primarily target the signaling pathways that con-
tribute to the disease onset independent of ASK1 pathway. It
would be an important issue to reveal the detailed signaling
pathways affected in the present treatment protocol and the
role of ASK1 in non-cell autonomous motoneuron death, as
well as the effects of #56-59 on the ASK1 pathway in in vitro
and in vivo.
#56 analogs preferentially interact with SOD1mut rather than
SOD1WT. Although we cannot exclude the possibility that #56
analogs inhibit the interaction of SOD1mut through the DBR not
only with Derlin-1 but also with other proteins, the SOD1-Derlin-
1 interaction is the most likely and promising target for ALS
treatment. It is also important to carefully interpret the speciﬁcity
of #56 analogs in cells or in vivo because of the very weak Kd
value of them (Supplementary Figure 7a). Further improvements
of #56 analogs’ afﬁnity to SOD1mut would be required. The elu-
cidation of compound-SOD1 complex atomic structure should
resolve these questions and facilitate further optimization of the
compounds.
We also found that zinc deﬁciency caused a conformational
change of SOD1WT to a mutant-like form (exposure of the DBR),
resulting in SOD1-Derlin-1 interaction28. Recently, it was
reported that conformationally disordered SOD1WT was observed
in SOD1 mutation-negative sporadic ALS (SALS) patients36.
SOD1WT has also been shown to be required for non-cell
autonomous motoneuron toxicity in astrocytes or oligoden-
drocytes derived from SALS patients37,38. These data suggest that
under certain conditions, including genetic factors and environ-
mental factors, SOD1WT may also serve as the cause of ALS
pathogenesis and that inhibition of the SOD1-Derlin-1 interac-
tion may be a potential target for ALS therapy development not
only for SOD1mut-caused FALS but also for a subset of SOD1
mutation-negative FALS and SALS, in which conformationally
disordered SOD1WT is proposed to be involved. To approach this
possibility, we investigated the effect of #56-59 on the iPSC-
derived motoneurons with TDP-43 mutant. However, consistent
with our previous observation that the exogenously expressed TDP-
43 mutants could not alter the SOD1WT conformation29, adminis-
tration of #56-59 did not improve motoneuron viability (Supple-
mentary Figure 8a). Since we cannot exclude the possibility that the
vulnerability masked the positive effect of #56-59 in ALS4, it is
important to evaluate the involvement of the SOD1-Derlin-1
interaction by using multiple inhibitors, different iPSC-derived
motoneurons, and/or other methods.
In summary, we succeeded in providing a proof-of-concept
regarding our SOD1-Derlin-1 interaction hypothesis by ameli-
orating the disease both in in vitro human model and in vivo
mouse model by using a developed PPI inhibitor. These data re-
emphasize the importance of the SOD1-Derlin-1 interaction as a
common mechanism of motoneuron toxicity in SOD1mut, and we
provided a potential approach for a molecular mechanism-based
ALS treatment.
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Methods
Plasmids. The complementary DNAs (cDNAs) encoding plasmids used in
developing the TR-FRET-based binding assay (Supplementary Table 1a, b)
were constructed in the pcDNA3.0 plasmid (Invitrogen) by PCR. The pcDNA3.0-
Derlin-1-HA, pcDNA3.0-Venus-Derlin-1(CT4)-HA, pcDNA3.0-Derlin-1-
Flag, pcDNA3.0-Derlin-2-Flag, pcDNA3.0-Derlin-3-Flag, pcDNA3.0-Flag-HRD1,
pcDNA3.0-Flag-SOD1WT, pcDNA3.0-Flag-SOD1mut, and pcDNA3.0-Flag-SOD1
(1-20)-CFP plasmids have been constructed in previous studies13,14. Transfection
was performed using Polyethylenimine-Max (Polysciences) according to the
manufacturer’s instructions.
Antibodies and peptides. Anti-tag antibodies labeled with either Eu or d2
(Supplementary Table 1c) were purchased from Cisbio. Horse radish peroxidase
(HRP)-linked anti-biotin antibody (7075, Cell Signaling Technology, dilution
1:2000) and antibodies against Flag tag (F3165, Sigma, dilution 1:10,000), HA tag
(11867431001, Roche, dilution 1:10,000), βIII-tubulin (MRB-435P, Covance,
dilution 1:2000), GFAP (N1506, DAKO, dilution 1:10), and Iba1 (019-19741,
Wako, dilution 1:500), SOD1 (ADI-SOD-100, Enzo Life Science, dilution 1:5000),
and Derlin-1 (SAB4200148, Sigma, 1.5 µg for immunoprecipitation) were pur-
chased from the indicated suppliers. The Derlin-1 antibody has been generated
previously (dilution 200 ng ml−1)13. The biotinylated SOD1 (5-20) peptide (biotin-
VCVLKGDGPVQGIINF) and biotinylated Derlin-1 (CT4) peptide (biotin-
CFLYRWLPSRRGG) were purchased from Euroﬁns.
Cell cultures. HEK293A cells were purchased from Invitrogen and were used due
to the high efﬁciency of lipofection. The cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 10% fetal bovine serum, 4.5 mgml−1 glucose,
and 100 Uml−1 penicillin, and maintained in an atmosphere of 5% CO2 at 37 °C.
HEK293A cells were tested for the presence of mycoplasma and identiﬁed by
morphology and efﬁcient production of adenovirus.
TR-FRET-based interaction assay. HEK293A cells transfected with Flag-
SOD1G93A and Derlin-1-HA or HA-SOD1WT-Flag were lysed in FRET buffer
containing 25 mM phosphate buffer pH 7.0, 400 mM potassium ﬂuoride, 0.1%
bovine serum albumin (BSA), 0.5% Triton X-100, 5 μg ml−1 leupeptin, 1 mM
phenylmethylsulfonyl ﬂuoride. In competition assay using biotinylated SOD1
(5-20) peptide and Derlin-1 (CT4) peptide, lysates from HEK293A cells transfected
with Flag-SOD1G93A and Derlin-1-HA were incubated with the indicated con-
centration of each peptide for 16 h. Then, the ﬂuorophore-labeled antibodies were
mixed, and FRET signals were measured. In the compound screen, lysates were
added in the 384-well plates (Greiner) in which compounds were dispensed in
advance. In the ﬁrst and second screening steps, compounds were tested at ﬁnal
concentrations of 50 µM in 0.25% DMSO by applying 250 nL of 2 mM stock
solution. In a 5-point dose–response experiment in the third screening, compound
concentrations were 150, 75, 37.5, 19, and 9.5 μM with 0.75% DMSO. After the
incubation at 4 °C for 12–16 h, the anti-Flag antibody labeled with Eu and the anti-
HA antibody labeled with d2 diluted in FRET buffer were added and incubated for
1 h at room temperature in 384-well plates. Then, the FRET intensity (337 nm
excitation ﬁlter/665 nm emission ﬁlter) and donor intensity (337 nm excitation
ﬁlter/620 nm emission ﬁlter) were measured using PHERAstar (BMG Labtech),
and the FRET ratio was calculated as FRET intensity/donor intensity. FRET signal
was the FRET ratio of DMSO-treated transfected cell lysates sample (FRET Ratio
Max) divided by that of lysate samples from non-transfected cells (FRET Ratio
Min). Inhibition (%) was calculated using the following equation: Inhibition (%)=
100−100 {(FRET Ratio of each tested compound)− (FRET Ratio Min)}/ {(FRET
Ratio Max)− (FRET Ratio Min)}. The number of samples represents technical
replicates.
Immunoblotting analysis. HEK293A cells were lysed on ice in a buffer containing
20mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM EDTA, 1% Triton X-100, 5 µgml−1
leupeptin, and 1 mM phenylmethylsulfonyl ﬂuoride. After centrifugation, cell
extracts were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
electroblotted onto polyvinylidene diﬂuoride membranes. After blocking with 5%
skim milk in TBS-T (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05% Tween-
20), the membranes were probed with antibodies to HA, Flag, α-tubulin, or biotin
(HRP-linked). The proteins were detected using the ECL system. IC50 values of #56
analogs in in vitro assay were calculated by generating standard curves, and ana-
lyses were performed using a ChemiDoc and Image Lab software (Bio-Rad). The
uncropped scans were supplied in Supplementary Figure 10. All immunoblotting
analyses were repeated at least three times and the same results were obtained.
In vitro immunoprecipitation analysis. HEK293A cell lysates transfected with
each plasmid were immunoprecipitated with anti-Flag beads (M2 Afﬁnity Gel,
Sigma). The beads were washed with washing buffer 1 (20 mM Tris-HCl, pH 7.5,
500 mM NaCl, 5 mM EGTA, and 1% Triton X-100) twice and a buffer containing
20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA, and 1% Triton X-100
once. Then, the SOD1-Derlin-1 complex was eluted by elution buffer (0.1% Triton
X-100, 500 mM NaCl, 20 mM Tris-HCl, pH 7.5, 5 mM EGTA, and 100 µg ml−1 1×
Flag peptide) and ultraﬁltered using Centrifugal Filters (Amicon Ultra 10K,
Millipore) to exclude the Flag peptide. After optimal dilution with dilution buffer
(0.01% Triton X-100, 500 mM NaCl, 20 mM Tris-HCl, pH 7.5, 5 mM EGTA),
SOD1-Derlin-1 complexes were incubated with compounds and immunoprecipi-
tated with anti-Flag beads (M2 Afﬁnity Gel, Sigma). The remaining SOD1-Derlin-1
complexes were separated by SDS-PAGE and analyzed via immunoblotting with
antibodies for HA or Flag.
Cell-based immunoprecipitation analysis. HEK293A cells transfected with each
plasmid were lysed as for the immunoblotting analysis, and lysates were immu-
noprecipitated with anti-Flag beads (M2 Afﬁnity Gel, Sigma). The beads were
washed twice with washing buffer 1 and then once with washing buffer 2 (20 mM
Tris-HCl, pH 7.5, 150 mM NaCl, and 5 mM EGTA), separated by SDS-PAGE, and
immunoblotted with antibodies for HA or Flag.
Immunoprecipitation analysis from mouse spinal cord. The mouse spinal cords
were homogenated on ice in a buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 10 mM EDTA, 1% Triton X-100, 5 µg ml−1 leupeptin, and 1 mM phe-
nylmethylsulfonyl ﬂuoride. The lysates were immunoprecipitated with anti-Derlin-
1 antibody with protein G-Sepharose (GE Healthcare). The beads were washed
three times with the lysis buffer, separated by SDS-PAGE, and immunoblotted with
antibodies for SOD1 or Derlin-1.
Compound treatment for immunoprecipitation assay. For the in vitro immu-
noprecipitation, compounds were added to puriﬁed SOD1-Derlin-1 complexes
from HEK293A cells at 4 °C for 16 h. For the cell-based immunoprecipitation,
compounds were added to the culture medium of HEK293A cells for 24 h.
Chemical compounds. Compound #56 (InterBioScreen Ltd), #56-20, and #56-26
(Vitas-M laboratory) were purchased. Other compounds were synthesized as
described in Supplementary Methods.
Permeability assay and metabolic stability assay. The permeability and meta-
bolic stability of the compounds were determined commercially using the CEREP
in vitro drug absorption and in vitro drug metabolism service, respectively.
Surface plasmon resonance. SPR was analyzed with Biacore T100 (GE Health-
care). The biotinylated SOD1 (5-20) peptide and biotinylated Derlin-1 (CT4)
peptide were captured as a ligand with Biotin CAPture Kit, Series S (GE Health-
care). #56-20 or #56-26 in a buffer containing 10 mM HEPES, pH 7.5, 150 mM
NaCl, 3 mM EDTA, 0.005% Tween-20, and 0.5% DMSO were ﬂowed as an analyte.
FP analysis. For FP analysis, 250 nM #56-20 was incubated with various con-
centrations of biotinylated SOD1 (5-20) peptide or biotinylated Derlin-1 (CT4)
peptide in a buffer containing 10 mM HEPES, pH 7.5, 150 mM NaCl, 3 mM EDTA,
and 0.005% Tween-20 for 6 h at room temperature in the 384-well plates (Greiner).
The FP (405 nm excitation ﬁlter/535 nm emission ﬁlter) was measured using an
ARVO X5 (Perkin Elmer). The experiment was repeated three times on three
separate days. Kd was calculated by the following equation39: P= PL+ [(PRL− PL)/
LT] × ½ [(LT+ RT+ Kd)− √ ((LT+ RT+ Kd)2− (4 × RT × LT))], where P is the
observed polarization value; PRL and PL are the polarization signals for fully bound
and displaced ligand; and LT and RT are total concentrations of #56-20 and
recombinant SOD1.
Pull-down assay for target identiﬁcation. HEK293A cells transfected with vector,
Flag-SOD1G93A, Flag-SOD1WT, or Derlin-1-Flag were treated with 200 μM PB56
for 24 h and then irradiated with 365-nm ultraviolet (UV) light for 1 h on ice. In
the competition assay, HEK293A cells transfected with Flag-SOD1G93A were
treated with 200 μM PB56 for 24 h with or without pre-treatment with 20 μM #56-
59 for 12 h and were irradiated with 365-nm UV light for 1 h. Cells were lysed in a
buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA, 1%
Triton X-100, 5 µg ml−1 leupeptin, and 1 mM phenylmethylsulfonyl ﬂuoride.
Recombinant proteins and SOD activity assay. The cDNAs encoding GST-
SOD1WT and GST-SOD1G93A were constructed in the pGEX-6P-1 vector (GE
Healthcare), and each plasmid was transformed into Escherichia coli (BL21). The
transformed cells were cultured in Luria Broth medium containing 50 μg ml−1
ampicillin at 37 °C for 16 h. Isopropyl β-D-1-thiogalactopyranoside was then added
at a ﬁnal concentration of 0.1 mM, and the cells were incubated at 30 °C for an
additional 2 h. Cells were lysed with chilled lysis buffer (phosphate-buffered saline
(PBS) containing 10 mM EDTA and 1% Triton X-100). After centrifugation at
17,700 × g, the supernatant was incubated with Glutathione Sepharose 4B (GE
Healthcare) at 4 °C for more than 2 h. After three washes with PBS containing
10 mM EDTA, proteins were eluted using the elution buffer (50 mM Tris-HCl, pH
8.0, and 10 mM L-glutathione). The proteins were incubated with 100 µM CuSO4
and ZnCl2, dialyzed using PBS, and incubated with DMSO and 50 µM #56-20 or
#56-26 at 4 °C for 16 h. SOD activity was measured using a SOD Assay Kit
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according to the manufacturer’s instructions (Dojindo). The experiment was
repeated three times on three separate days.
Motoneuron survival assay using iPSCs. Use of human iPSCs was approved by
the Ethics Committees of the respective departments at Kyoto University. All
methods were performed in accordance with approved guidelines. Informed con-
sent was obtained from all subjects. Motoneurons were generated from previously
established iPSCs by introducing transcription factors Lhx3, Ngn2, and Isl1 under
the control of tetracycline31. Some iPSC clones, Control 1, ALS1, ALS2, and ALS4,
are deposited into RIKEN BioResource Center (depository numbers are HPS0063,
HPS0251, HPS0252, and HPS0292, respectively). The compound screen was pre-
viously established31. The iPSCs were dissociated to single cells using Accutase
(Innovative Cell Technologies, San Diego, CA, USA) and plated onto Matrigel-
coated 96-well plates (Corning, Corning, NY, USA) with neuronal medium
(DMEM/F12 (Thermo Fisher Scientiﬁc), 100 μg ml−1 apotransferrin (Sigma),
5 μg ml−1 insulin (Sigma), 30 nM selenite (Sigma), 20 nM progesterone (Sigma),
100 nM putrescine (Sigma)) containing 1 μM retinoic acid (Sigma), 1 μM
smoothened agonist), 10 ng ml−1 brain-derived neurotrophic factor (R&D Systems,
Minneapolis, MN, USA), 10 ng ml−1 glial cell-derived neurotrophic factor (R&D
Systems), and 10 ng ml−1 NT-3 (R&D Systems) with 1 μg ml−1 doxycycline
(TAKARA), and cultured for 7 days. Compounds were added to cells on day 7, and
cultures were continued until day 14. Cells were ﬁxed and stained on days 7 and 14.
The number of surviving motoneurons stained with βIII-tubulin (Covance, Prin-
ceton, NJ, USA) was quantiﬁed by IN Cell Analyzer 6000 (GE Healthcare, Chicago,
IL, USA) and IN Cell Developer toolbox software 1.9 (GE Healthcare).
Animals. All experiments were performed in accordance with protocols approved
by the Animal Research Committee of the Graduate School of Pharmaceutical
Sciences, The University of Tokyo (Tokyo, Japan). The mouse genotypes were
veriﬁed by PCR at weaning and before the administration of compounds. At
22 weeks of age, approximately 6 weeks before the usual onset timing as deﬁned in
our previous study13, male mice with the human SOD1G93A transgene (G1L/+
line, backcrossed to C57BL/6) were randomly separated into three groups and
continuously infused with DMSO as control, with 1 mM #56-40, or with 3 mM
#56-59, using osmotic pumps (ﬂow rate 0.15 μl h−1, Alzet Mode 2006) by i.c.v.
cannulation with the Brain Infusion Kit 3 (Alzet). Pumps were placed on the back
of the mouse and were replaced every 6 weeks until the mouse showed paralysis.
Onset was determined at the time point when the average of week’s rotarod per-
formance (three times per week) began to decline at an accelerated speed to 40 rpm
for 5 min. The genotype of the mouse that did not show any symptoms was again
conﬁrmed by PCR, and the treatment trial of this mouse was stopped at 58 weeks
of age. The investigators were not blinded to allocation during experiments and
outcome assessment.
Measurement of #56-59 concentration. Male mice (C57BL/6) were con-
tinuously infused with 3 mM #56-59 using osmotic pumps by i.c.v. cannulation.
The brain and spinal cord were extirpated at 1, 3, and 5 weeks after the start of the
infusion and homogenized with phosphate buffer. The tissue homogenates were
deproteinized with acetonitrile containing the internal standard (methyltestoster-
one) and centrifuged at 10,000 × g for 5 min at 4 °C. The supernatants were sub-
jected to liquid chromatography-tandem triple quadrupole mass spectrometry
analysis (LCMS-8060, Shimadzu, Japan) to quantify the concentration of #56-59 in
the brain and spinal cord. The samples that were below the detection limit (Sup-
plementary Table 2) were eliminated in the Supplementary Figure 8b.
Nissl staining and immunohistochemistry. Mice were perfused with PBS and
then with 4% paraformaldehyde (PFA) in PBS and the spinal cords (L2–L5) were
ﬁxed with 4% PFA in PBS for 1 day. The lumbar spinal cords were then incubated
in 30% sucrose for 24 h, embedded in CryoMount I (Muto PureChemicals), and
frozen sections (40 μm) were produced. Nissl stained were performed using 0.1%
cresyl violet acetate (WALDECK). Motoneurons showing a clear nucleolus and
distinctly labeled cytoplasm with neuronal morphology, with cell bodies >20 μm in
diameter and located in the anterior horn, were included in cell counts. All
motoneuron counts were performed in a blinded fashion. For the immunohis-
tochemistry, frozen sections were blocked with 1% BSA at room temperature, and
each section was incubated with the primary antibodies. After three washes with
PBS, sections were incubated with the secondary antibody solution at room tem-
perature. All images were obtained using a Leica TCS SP5 confocal laser scanning
microscope.
Statistical analysis. No statistical methods were used to predetermine sample size.
Motoneurons survival assay were analyzed using one-way analysis of variance
followed by Tukey’s post hoc test (with similar variance) or Kruskal–Wallis fol-
lowed by Dunn's test (#56-59-treated ALS1 with non-similar variance) to deter-
mine statistical signiﬁcances of the data (n= 6; p < 0.05, post hoc test, *p < 0.05).
Onset and survival were statistically analyzed using the Kaplan–Meier method
followed by the log-rank test and the Gehan–Breslow–Wilcoxon test (*p < 0.05). To
ensure randomization of spinal cord section for motoneurons count, the ﬁve frozen
sections of L2 to L5 were randomly chosen (WT mice (34 weeks old): n= 4;
DMSO-treated and #56-59-treated SOD1G93A transgenic mice (31 weeks old):
n= 8 per group, *p < 0.05: the signiﬁcance with similar variance was evaluated
using unpaired, two-tailed Student’s t test).
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request.
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